Nasdaq · CIK 0001679628
JUNS JUPITER NEUROSCIENCES, INC.
Insider trading from SEC Form 4. Last filing Jun 5, 2026. Close $2.85 on Oct 9, 2026, +18% from the 52-week low and -98% from the high.
JUPITER NEUROSCIENCES, INC. (JUNS) has 10 SEC Form 4 filings on file from 5 insiders, the latest filed on Jun 5, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at JUNS. The newest: Christer Rosen (CEO and Chairman) bought $3,667 of stock on Jul 1, 2025, filed Jul 3, 2025, scored 33 (weak). The largest of the 4 shown: Christer Rosen (CEO and Chairman) bought $7,986 on Jun 27, 2025, scored 28 (weak). 2 insiders bought within 14 days of each other around Jul 1, 2025.
JUNS closed at $2.85 on Oct 9, 2026, 18% above its 52-week low and 98% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at JUPITER NEUROSCIENCES, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Christer Rosen CEO and Chairman buy | $3,667 3,600 shares | +0% | - | |
| 23Weak | Alison D. Silva Pres + Chief Business Officer buy | $772 750 shares | +1% | - | |
| 28Weak | Christer Rosen CEO and Chairman buy | $7,986 7,816 shares | +0% | - | |
| 23Weak | Alison D. Silva Pres + Chief Business Officer buy | $1,855 1,800 shares | +2% | - |
Transactions
Every row filed, 33 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Allison W Brady director | AGrant or award Stock Optionderivative | +100,000 | $0.00 | $0 | 100,000 | Jun 5, 2026 |
| Jun 2, 2026 | Saleem Elmasri Chief Financial Officer | AGrant or award Stock Optionderivative | +525,565 | $0.00 | $0 | 525,565 | Jun 4, 2026 |
| Jul 2, 2025 | Alison D. Silva Pres + Chief Business Officer | AGrant or award Stock Option (right to buy)derivative | +255,320 | - | - | 255,320 | Jul 7, 2025 |
| Jun 2, 2025 | Saleem Elmasri CFO and Secretary | MOption exercise Common Stock | +66,293 | $0.00 | $0 | 66,239 | Jul 7, 2025 |
| Jul 2, 2025 | Saleem Elmasri CFO and Secretary | AGrant or award Stock Option (right to buy)derivative | +102,128 | - | - | 102,128 | Jul 7, 2025 |
| Jul 1, 2025 | Christer Rosen CEO and Chairman | POpen-market purchase Common Stock | +500 | $1.01 | $505 | 11,075,792 | Jul 3, 2025 |
| Jul 1, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +250 | $1.03 | $257 | 112,277 | Jul 3, 2025 |
| Jul 1, 2025 | Christer Rosen CEO and Chairman | POpen-market purchase Common Stock | +3,100 | $1.02 | $3,162 | 11,078,892 | Jul 3, 2025 |
| Jul 1, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +250 | $1.03 | $257 | 112,527 | Jul 3, 2025 |
| Jul 1, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +250 | $1.03 | $259 | 112,777 | Jul 3, 2025 |
| Jun 2, 2025 | Alison D. Silva Pres + Chief Business Officer | MOption exercise Common Stock | +110,227 | $0.00 | $0 | 110,227 | Jul 1, 2025 |
| Jun 2, 2025 | Christer Rosen CEO and Chairman | MOption exercise Common Stock | +497,396 | $0.00 | $0 | 10,591,406 | Jul 1, 2025 |
| Jun 27, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +250 | $1.00 | $250 | 110,477 | Jul 1, 2025 |
| Jun 2, 2025 | Christer Rosen CEO and Chairman | MOption exercise Common Stock | +476,070 | $0.00 | $0 | 11,067,476 | Jul 1, 2025 |
| Jun 27, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +100 | $1.04 | $104 | 110,577 | Jul 1, 2025 |
| Jun 27, 2025 | Christer Rosen CEO and Chairman | POpen-market purchase Common Stock | +166 | $1.06 | $176 | 11,067,642 | Jul 1, 2025 |
| Jun 27, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +250 | $1.04 | $261 | 110,827 | Jul 1, 2025 |
| Jun 30, 2025 | Christer Rosen CEO and Chairman | POpen-market purchase Common Stock | +1,000 | $0.98 | $980 | 11,068,642 | Jul 1, 2025 |
| Jun 27, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +250 | $1.05 | $263 | 111,077 | Jul 1, 2025 |
| Jun 30, 2025 | Christer Rosen CEO and Chairman | POpen-market purchase Common Stock | +2,000 | $1.01 | $2,020 | 11,070,642 | Jul 1, 2025 |
| Jun 30, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +100 | $1.02 | $102 | 111,177 | Jul 1, 2025 |
| Jun 30, 2025 | Christer Rosen CEO and Chairman | POpen-market purchase Common Stock | +1,450 | $1.02 | $1,479 | 11,072,092 | Jul 1, 2025 |
| Jun 30, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +250 | $1.02 | $255 | 111 | Jul 1, 2025 |
| Jun 30, 2025 | Christer Rosen CEO and Chairman | POpen-market purchase Common Stock | +700 | $1.03 | $721 | 11,072,792 | Jul 1, 2025 |
| Jun 30, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +250 | $1.03 | $258 | 111,677 | Jul 1, 2025 |
| Jun 30, 2025 | Christer Rosen CEO and Chairman | POpen-market purchase Common Stock | +1,500 | $1.04 | $1,560 | 11,074,292 | Jul 1, 2025 |
| Jun 30, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +250 | $1.04 | $259 | 111,927 | Jul 1, 2025 |
| Jun 30, 2025 | Christer Rosen CEO and Chairman | POpen-market purchase Common Stock | +1,000 | $1.05 | $1,050 | 11,075,292 | Jul 1, 2025 |
| Jun 30, 2025 | Alison D. Silva Pres + Chief Business Officer | POpen-market purchase Common Stock | +100 | $1.05 | $105 | 112,027 | Jul 1, 2025 |
| Jan 22, 2025 | Allison W Brady director | MOption exercise Common Stock, par value $0.0001 per share | +21,750 | - | - | 21,750 | Jan 24, 2025 |
| Jan 22, 2025 | Holger Weis director | MOption exercise Common Stock, par value $0.0001 per share | +10,781 | - | - | 10,781 | Jan 24, 2025 |
| Jan 22, 2025 | Allison W Brady director | MOption exercise Convertible Notesderivative | -21,750 | $2.80 | $61k | 21,750 | Jan 24, 2025 |
| Jan 22, 2025 | Holger Weis director | MOption exercise Convertible Notesderivative | -10,781 | $2.80 | $30k | 10,781 | Jan 24, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Allison W Bradydirector
- Saleem ElmasriChief Financial Officer
- Christer RosenCEO and Chairman
- Alison D. SilvaPres + Chief Business Officer
- Holger Weisdirector, ceo, officer
Questions about JUNS
Answered from the filings on this page, as of the latest one.
Are insiders buying JUNS?
No. In the last 90 days no insider at JUPITER NEUROSCIENCES, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade JUNS on the open market?
Christer Rosen (CEO and Chairman) bought $3,667 of JUNS on Jul 1, 2025 and filed the Form 4 on Jul 3, 2025. InsiderTell scored 33 (weak), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at JUPITER NEUROSCIENCES, INC.?
5 people have filed a Form 4 at JUPITER NEUROSCIENCES, INC., among them Allison W Brady (director), Saleem Elmasri (Chief Financial Officer), Christer Rosen (CEO and Chairman). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.